Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53

被引:5
|
作者
Almazi, Juhura G. [1 ]
Mactier, Swetlana [1 ]
Best, O. Giles [2 ]
Crossett, Ben [1 ]
Mulligan, Stephen P. [1 ,2 ]
Christopherson, Richard I. [1 ]
机构
[1] Univ Sydney, Sch Mol Biosci, Sydney, NSW 2006, Australia
[2] Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia
关键词
B-lymphoproliferative disorders; Fludarabine; p53; p63; p73; CHRONIC LYMPHOCYTIC-LEUKEMIA; TUMOR-SUPPRESSOR; DNA-DAMAGE; APOPTOSIS; EXPRESSION; DEATH; GENE; ISOFORMS; PROTEIN; CANCER;
D O I
10.1002/prca.201200003
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Purpose Human Raji cells treated with fludarabine nucleoside (2-FaraA, 3 mu M) undergo apoptosis with accumulation of p53 in the nuclei as multiple phosphorylated isoforms and C-terminal truncated derivatives. Changes induced by 2-FaraA in the levels of p53, p63 and p73 in the nuclear, cytosolic and mitochondrial fractions have been determined in four human B-lymphoid cell lines that are TP53-functional (Raji and IM9) and TP53-mutated (MEC1 and U266). Experimental design The B-lymphoid cell lines were treated with 2-FaraA (3 mu M, 24 h, 48 h) and viability determined. Protein extracts of subcellular fractions from 2-FaraA-treated cells were analysed by 1D and 2D electrophoresis; multiple phosphorylated isoforms and truncated derivatives were identified by Western blots for p53, p63 and p73. Results p53 and p63 were present in all three fractions, while p73 was only detected in nuclei. After treatment with 2-FaraA, nuclear p53, p63 and p73 accumulated as multiple phosphorylated isoforms and truncated derivatives. The association of p63 with mitochondria in human cells is novel. Conclusions and clinical relevance Comprehensive information on the subcellular distributions and responses of p53, p63 and p73 to 2-FaraA provides additional insight into mechanisms for induction of apoptosis in the treatment of B-lymphoproliferative disorders with fludarabine.
引用
收藏
页码:279 / 290
页数:12
相关论文
共 50 条
  • [21] p53 family update: p73 and p63 develop their own identities
    Irwin, MS
    Kaelin, WG
    CELL GROWTH & DIFFERENTIATION, 2001, 12 (07): : 337 - 349
  • [22] Structural evolution of p53, p63, and p73: Implication for heterotetramer formation
    Joerger, Andreas C.
    Rajagopalan, Sridharan
    Natan, Eviatar
    Veprintsev, Dmitry B.
    Robinson, Carol V.
    Fersht, Alan R.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (42) : 17705 - 17710
  • [23] Mutational analysis of p73 and p53 in human cancer cell lines
    Yoshikawa, H
    Nagashima, M
    Khan, MA
    McMenamin, MG
    Hagiwara, K
    Harris, CC
    ONCOGENE, 1999, 18 (22) : 3415 - 3421
  • [24] Mutational analysis of p73 and p53 in human cancer cell lines
    Hirohide Yoshikawa
    Makoto Nagashima
    Mohammed A Khan
    Mary G McMenamin
    Koichi Hagiwara
    Curtis C Harris
    Oncogene, 1999, 18 : 3415 - 3421
  • [25] Differential expression of p53, p63 and p73 proteins in human buccal squamous-cell carcinomas
    Chen, YK
    Huse, SS
    Lin, LM
    CLINICAL OTOLARYNGOLOGY, 2003, 28 (05) : 451 - 455
  • [26] Expression profiles of p53, p63, and p73 in benign salivary gland tumors
    Anette Weber
    Larissa Langhanki
    Alexander Schütz
    Andreas Gerstner
    Friedrich Bootz
    Christian Wittekind
    Andrea Tannapfel
    Virchows Archiv, 2002, 441 : 428 - 436
  • [27] P53, p63 and p73 - solos, alliances and feuds among family members
    Moll, UM
    Erster, S
    Zaika, A
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2001, 1552 (02): : 47 - 59
  • [28] The Tumor Suppressors p53, p63, and p73 Are Regulators of MicroRNA Processing Complex
    Boominathan, Lakshmanane
    PLOS ONE, 2010, 5 (05):
  • [29] p73, a grandpa of p53?
    Soussi, T
    M S-MEDECINE SCIENCES, 1997, 13 (12): : 1472 - 1473
  • [30] Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?
    Y Li
    C Prives
    Oncogene, 2007, 26 : 2220 - 2225